Taveras Arthur
Known title: Chief Scientific OfficerCIK: 0001830901
Associated companies
Transaction History
| XFOR | ▼ Sell | Open Market | 76,920 | $43K | 10/7/2024 | View on chart |
| XFOR | ▲ Buy | Grant | 230,645 | $0 | 10/4/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 14,235 | $13K | 3/11/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 787 | $793 | 2/12/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 67,695 | $49K | 11/1/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 230,645 | $0 | 10/31/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 16,806 | $14K | 3/10/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 928 | $863 | 2/13/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 97,000 | $0 | 3/1/2022 | View on chart |
| XFOR | ▼ Sell | Tax Withholding | 928 | $0 | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.